Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma - Wikidata - awgldk - TriplyDB

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

http://www.wikidata.org/entity/Q24631455

about

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.Therapies targeting cancer stem cells: Current trends and future challenges Normal and neoplastic urothelial stem cells: getting to the root of the problem Immunotargeting of cancer stem cells Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer CD47 expression in cryopreserved equine cutaneous masses and normal skin Registered report: the CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors Clinically Relevant Molecular Subtypes in Leiomyosarcoma T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.Dystrophin is a tumor suppressor in human cancers with myogenic programs.Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.Human cancer growth and therapy in immunodeficient mouse models."Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.Macrophages are critical effectors of antibody therapies for cancer Original insights on thrombospondin-1-related antireceptor strategies in cancer.Potential Therapeutic Targets in Uterine Sarcomas.Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth CD47 signaling pathways controlling cellular differentiation and responses to stress.Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma Primary thyroid leiomyosarcoma: A case report and literature review.Monocytes and macrophages in cancer: development and functions CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer.The use of CD47-modified biomaterials to mitigate the immune response.Autophagy proteins regulate cell engulfment mechanisms that participate in cancer.Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level.Myeloid Cell Origins, Differentiation, and Clinical Implications.Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues.

P2860

Q24602822-EC84C9F8-A397-44C2-B493-3124D54621B6 Q24605057-4237CCCD-1DA0-43E5-AD79-0A79E3335406 Q26777880-1E003FFB-7203-4A15-86B3-006069262E57 Q26825948-10075DC7-9028-4906-96CB-A41D7361CFA8 Q27014031-87DEEBBA-6D2A-442B-8542-1A94EC0C927D Q27021570-DC1222DF-FB38-4E29-B046-D140494F7153 Q28073257-2C7EC7A5-CFDA-41CE-B82D-96D60B5BE8C1 Q28275412-22808EB5-6E75-4D0A-AFC4-275E275D20A3 Q28650496-4595A629-A086-464B-A970-5887F212E36D Q30300155-34FFD426-461C-477E-A3E9-5DF727A2DB15 Q30491565-11EC3F3A-2385-439D-AFC9-CA278D3327FC Q33558122-138A84A2-03F4-44A9-87A5-BCA6F66CEAB4 Q34479070-3FC1615A-749D-4B73-8A01-C3608003E3AC Q34483478-1008F193-DD1B-41A8-90BB-909BA306B32F Q34548156-325A4D80-7E22-410D-BCA2-7C6245D7C034 Q34553348-6852DA39-F687-4E60-8D70-0329E9FB86B3 Q34621578-1482E7A2-DE05-4E9F-AD78-BC187C630A38 Q35056301-1D8FF3C4-4050-49E2-96C4-3025F4CDEB26 Q35129097-D54E7452-FB83-4EE0-BADE-DD4B25C8642A Q35545282-AF887225-293B-45EA-9F44-0AA4BC1F3DF1 Q35608098-C404A815-4503-4D13-A06B-3F5D2CC7CAD5 Q35781873-13851D27-B6FE-4F70-9015-DA4CFCFBD842 Q35837348-079275BB-F815-4AFA-A952-BE2755FAD186 Q36051761-E3F54B88-E54E-46AE-8EFE-72A072A1E07D Q36208486-92B5B653-4818-4F14-87A2-7535298305F9 Q36213288-E3C8D958-2FC4-4981-ABAD-E2DD7E1A62EE Q36221374-153A89BE-55EB-430B-BFAD-723308E47A82 Q36245677-00D827C9-A5F7-458E-9641-85C277067E11 Q36653990-C82164A8-8844-4BFC-9B83-C0EAB942CB9B Q36771076-BA6BE952-AE2B-43A9-AC06-86469A42E3FA Q36950772-9E3F7AEF-8E45-4296-ACBB-211555DD9C28 Q36954580-E3696317-77D5-406F-B803-36978B49E8D1 Q37028772-334AB71C-7721-4D62-A2D5-4B1EB246332B Q37093349-4D21D553-6EA0-4B7C-A16F-D45C5668291A Q37107151-F62AB00E-60A0-443E-83B3-297450C57DF2 Q37216731-6D6AA26D-A094-4AE5-B9B4-65262AFF272A Q37254863-56304040-B87F-4441-8C64-E6017B315A55 Q37393282-1B59B4B7-D63E-46CF-B270-62F68FBAA200 Q37429070-0088E9DC-4BCF-4F32-811C-3AA67B4E360E Q37543916-A3CC4775-F58B-452D-82B1-70CD35C6E42F

P2860

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

http://www.wikidata.org/entity/Q24631455

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@ast

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@en

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@nl

type

label

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@ast

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@en

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@nl

prefLabel

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@ast

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@en

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@nl

P1433

Q24631455-F91BB62B-309C-45FB-83E2-A7E6B4ACE9C0

P1476

Q24631455-4A4510DE-9A74-4039-91B8-3C584F310427

P2093

Q24631455-1C302EDA-44BB-45B9-86F4-CDCC7792645E

Q24631455-4F79398F-67A9-4291-A03C-3E8E5D906B3D

Q24631455-4FC75728-1EB7-4DC6-BEE5-47117AF2D71F

Q24631455-54D5B2E0-CE1A-40E9-8BCF-EA745BFE814C

Q24631455-5CF7BB00-E0C3-4D96-846A-31CAEDD26544

Q24631455-6F2E183A-0416-4078-B630-29F854AE82FA

Q24631455-79E29A23-02CD-44F2-8ECD-DA10E0265F8F

Q24631455-9FD217E5-37F3-4873-98DC-2ADC7DFEE532

Q24631455-A6FF8544-B553-4BD9-92BA-79E639CF653A

Q24631455-B473CD61-2801-4B40-A3FA-40A6A15E7CF4

P2860

Q24631455-00F12D3C-56FA-42E2-8C5B-157B8B5B0C19

Q24631455-0125AFA6-EF38-4738-975A-F17A2DAE9256

Q24631455-05805C5F-C0EE-4A9D-B108-0AA45EC4509B

Q24631455-2509B436-CF61-4D8A-BDC2-C3C9D42E25C8

Q24631455-2704964A-2395-45E1-BC63-1387E2D9785E

Q24631455-38E2D644-BCFF-4B91-82BB-1E5BA345DE2D

Q24631455-3B31AB39-05AD-427A-AEA3-DA7D5ABB27C7

Q24631455-4F923D7D-A8B2-4D6F-A55D-5C2F88D77BDF

Q24631455-5D3D18A3-E07B-45B3-9A70-CF97E47266FE

Q24631455-654A76E8-54B3-4EF3-A4B7-ABCB6C0195A7

P304

Q24631455-74C35DB2-0F4A-4802-AAB2-EEA146FD2392

P31

Q24631455-A6488ED3-7B4D-4E37-B903-F7AEE0DE6AD8

P3181

Q24631455-5CA32A9D-A5EF-42E2-B3F8-33BD7C989FB7

P356

Q24631455-386B0183-CAF0-4B94-BE87-E28FC1F429B9

P407

Q24631455-6F824AF7-4D06-4380-A725-C7711ECC12EB

P433

Q24631455-22F2E858-613D-4C78-9945-303BDE70D0BD

P478

Q24631455-04A37DC4-F848-46F2-8915-050521805727

P50

Q24631455-94CF1D48-7128-4061-A568-161573BC1869

P577

Q24631455-8EC264AB-B464-4945-89C2-75FAED776C17

P5875

Q24631455-DF94284E-A69B-469B-A542-7FCC6A7145E0

P698

Q24631455-EAC6F521-48A9-4FD0-B3C0-6B5ED9DF7A51

P921

Q24631455-85732540-779B-4C0F-995E-E0F3ACD46070

P932

Q24631455-F14B85F7-760F-43B6-8C4A-E42755E35BD8

P3181

P356

PNAS.1121629109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Antibody therapy targeting the ...... sive metastatic leiomyosarcoma

@en

P2093

Andrew H Beck

http://www.w3.org/2001/XMLSchema#string

Anne K Volkmer

http://www.w3.org/2001/XMLSchema#string

Badreddin Edris

http://www.w3.org/2001/XMLSchema#string

Humberto Contreras-Trujillo

http://www.w3.org/2001/XMLSchema#string

Irving L Weissman

http://www.w3.org/2001/XMLSchema#string

Jens-Peter Volkmer

http://www.w3.org/2001/XMLSchema#string

Jie Liu

http://www.w3.org/2001/XMLSchema#string

Jonathan A Fletcher

http://www.w3.org/2001/XMLSchema#string

Kipp Weiskopf

http://www.w3.org/2001/XMLSchema#string

Ravindra Majeti

http://www.w3.org/2001/XMLSchema#string

P2860

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells

Integrin-associated protein (CD47) and its ligands

The SIRP family of receptors and immune regulation

Distinct role of macrophages in different tumor microenvironments

Macrophage diversity enhances tumor progression and metastasis

Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

Clonal analysis of mouse development reveals a polyclonal origin for yolk sac blood islands.

P304

6656-6661

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2066069

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.1121629109

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Matt van de Rijn

P577

2012-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221983374

http://www.w3.org/2001/XMLSchema#string

P698

22451919

http://www.w3.org/2001/XMLSchema#string

P921

P932

3340056

http://www.w3.org/2001/XMLSchema#string